Amit Fadia, MD
Nephrology · Tucson, AZNPI 1316984339
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,156 of the $4,921 with a category attached, or 84.4%. It is spread thinly across 24 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.
Across 250 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$884
- OPKO Pharmaceuticals, LLC$754
- AstraZeneca$740
- Fresenius USA Marketing, Inc.$429
- Vifor Pharma, Inc.$392
- Aurinia Pharma U.S., Inc.$269
- plus $1K from 18 others
Across 37 payments — averaging $10,572 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$235K
- Merck$66K
- Vertex$49K
- AstraZeneca$21K
- Novo Nordisk AS$20K
What the payments were for
- Food & beverage$4,15684%
- Education$76616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 56 | $884 |
| OPKO Pharmaceuticals, LLC | 44 | $754 |
| AstraZeneca(2 entities) | 31 | $740 |
| Fresenius USA Marketing, Inc. | 23 | $429 |
| Vifor Pharma, Inc. | 20 | $392 |
| Aurinia Pharma U.S., Inc. | 9 | $269 |
| Amgen(2 entities) | 12 | $220 |
| Travere Therapeutics, Inc. | 9 | $186 |
| Boehringer Ingelheim | 7 | $164 |
| Otsuka America Pharmaceutical, Inc. | 9 | $149 |
| Novartis | 7 | $131 |
| Calliditas Therapeutics US Inc. | 5 | $105 |
| Nxstage Medical, Inc. | 1 | $100 |
| Novo Nordisk | 3 | $86 |
| GSK | 3 | $74 |
| Akebia Therapeutics Inc | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Cormedix Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Amicus Therapeutics, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Insmed, Inc. | 1 | $19 |
| Sanofi | 1 | $17 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$250
- LUPKYNIS$126
- NXSTAGE SYSTEM ONE$100
How this compares
$4,921 in reported general payments places this provider in the 75th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 190 | $161,074 |
| VeltassaPatiromer Calcium Sorbitex | 47 | $68,850 |
| RayaldeeCalcifediol | 47 | $61,277 |
| LokelmaSodium Zirconium Cyclosilicate | 48 | $44,713 |
| VelphoroSucroferric Oxyhydroxide | 13 | $26,570 |
| DapagliflozinDapagliflozin Propanediol | 22 | $11,189 |
| Sevelamer Carbonate | 50 | $8,618 |
| Calcitriol | 213 | $3,132 |
| Fluconazole | 39 | $2,903 |
| Potassium Citrate ErPotassium Citrate | 18 | $2,210 |
| Midodrine Hcl | 34 | $1,980 |
| Amlodipine Besylate | 133 | $898 |
| Furosemide | 145 | $786 |
| Potassium Chloride | 32 | $759 |
| Hydralazine Hcl | 82 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $740 | $205,787238 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $754 | $61,27747 claims |
| Fresenius USA Marketing, Inc.Velphoro | $429 | $26,57013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 259 nephrology providers in Arizona.
Other nephrology in Tucson
- Aneesha ShettyTucson$34K
- David WhittmanTucson$13K
- Bijin ThajudeenTucson$7K
- Mindy JanTucson$7K
- Tausif ZarTucson$6K
- Vincent CampionTucson$5K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.